{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T22:05:36Z","timestamp":1766268336852},"reference-count":11,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"},{"start":{"date-parts":[[2018,1,8]],"date-time":"2018-01-08T00:00:00Z","timestamp":1515369600000},"content-version":"vor","delay-in-days":38,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Dermatol"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1111\/bjd.16033","type":"journal-article","created":{"date-parts":[[2018,1,13]],"date-time":"2018-01-13T03:31:07Z","timestamp":1515814267000},"page":"1474-1475","source":"Crossref","is-referenced-by-count":5,"title":["Brentuximab vedotin is an effective therapy for CD30<sup>+<\/sup>\n mycosis fungoides and cutaneous anaplastic large-cell lymphoma: what is the cost?"],"prefix":"10.1093","volume":"177","author":[{"given":"J.J.","family":"Scarisbrick","sequence":"first","affiliation":[{"name":"University Hospital Birmingham; Birmingham U.K."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2018,1,8]]},"reference":[{"key":"10.1111\/bjd.16033-BIB0001|bjd16033-cit-0001","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1056\/NEJMoa1002965","article-title":"Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas","volume":"363","author":"Younes","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1111\/bjd.16033-BIB0002|bjd16033-cit-0002","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1200\/JCO.2011.38.0410","article-title":"Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma","volume":"30","author":"Younes","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1111\/bjd.16033-BIB0003|bjd16033-cit-0003","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1200\/JCO.2011.38.0402","article-title":"Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study","volume":"30","author":"Pro","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1111\/bjd.16033-BIB0004|bjd16033-cit-0004","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1111\/bjd.15801","article-title":"Brentuximab vedotin in CD30+ cutaneous lymphoma: How do we treat, how shall we treat? A review of the literature","volume":"177","author":"Stranzenbach","year":"2017","journal-title":"Br J Dermatol"},{"key":"10.1111\/bjd.16033-BIB0005|bjd16033-cit-0005","doi-asserted-by":"crossref","first-page":"3759","DOI":"10.1200\/JCO.2014.60.3787","article-title":"Results of a phase II trial of brentuximab vedotin for CD30+ cutaneous T-cell lymphoma and lymphomatoid papulosis","volume":"33","author":"Duvic","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1111\/bjd.16033-BIB0006|bjd16033-cit-0006","doi-asserted-by":"crossref","first-page":"3750","DOI":"10.1200\/JCO.2014.60.3969","article-title":"Phase II investigator-initiated study of brentuximab vedotin in mycosis fungoides and S\u00e9zary syndrome with variable CD30 expression level: a multi-institution collaborative project","volume":"33","author":"Kim","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1111\/bjd.16033-BIB0007|bjd16033-cit-0007","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S0140-6736(17)31266-7","article-title":"Brentuximab vedotin in patients with CD30-expressing cutaneous T-cell lymphoma versus methotrexate or bexarotene: the phase 3 ALCANZA study","volume":"390","author":"Prince","year":"2017","journal-title":"Lancet"},{"key":"10.1111\/bjd.16033-BIB0008|bjd16033-cit-0008","unstructured":"National Institute for Health and Care Excellence Brentuximab https:\/\/bnf.nice.org.uk\/#Search?q=brentuximab"},{"key":"10.1111\/bjd.16033-BIB0009|bjd16033-cit-0009","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ejca.2017.02.027","article-title":"European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides\/S\u00e9zary syndrome","volume":"77","author":"Trautinger","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1111\/bjd.16033-BIB0010|bjd16033-cit-0010","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.2217\/fon-2017-0263","article-title":"Brentuximab vedotin therapy for CD30-positive cutaneous T-cell lymphoma: a targeted approach to management","volume":"13","author":"Scarisbrick","year":"2017","journal-title":"Future Oncol"},{"key":"10.1111\/bjd.16033-BIB0011|bjd16033-cit-0011","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1093\/annonc\/mdx352","article-title":"Global patterns of care in advanced stage mycosis fungoides\/S\u00e9zary syndrome: a multicenter retrospective follow-up study from the Cutaneous Lymphoma International Consortium","volume":"28","author":"Quaglino","year":"2017","journal-title":"Ann Oncol"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjd.16033","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/bjd.16033\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T14:30:07Z","timestamp":1676385007000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/177\/6\/1474\/6697340"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":11,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,12]]}},"URL":"https:\/\/doi.org\/10.1111\/bjd.16033","archive":["Portico"],"relation":{},"ISSN":["0007-0963"],"issn-type":[{"value":"0007-0963","type":"print"}],"subject":[],"published":{"date-parts":[[2017,12]]}}}